Points for Consideration for dengue vaccine introduction – recommendations by the Dengue Vaccine Initiative

ABSTRACT

Dengue is a public health problem in the tropics and subtropics. There are several vaccine candidates in clinical development. However, there may be gaps in the new vaccine introduction after vaccine licensure before it becomes available in developing countries. In anticipation of the first dengue vaccine candidate to be licensed, Dengue Vaccine Initiative (DVI) and, its predecessor, Pediatric Dengue Vaccine Initiative (PDVI) have been working on points for consideration to accelerate evidence-based dengue vaccine introduction, once a vaccine becomes available. In this paper, we review the history of PDVI and its successor, the DVI, and elaborate on the points of consideration for dengue vaccine introduction.

KEYWORDS:

• Dengue
• vaccine
• introduction
• Dengue Vaccine Initiative
• points for consideration

Acknowledgements

We would like to acknowledge members of the Americas and Asia-Pacific Dengue Prevention Boards for their contribution to develop the Points for Consideration. We also thank the partners of the DVI consortium, DVI NRA group, Dr. Liliana Chocarro and participants of the DVI DPB meetings for their input.

Financial & competing interests disclosure

This work was supported by grants from the Bill and Melinda Gates Foundation to the Dengue Vaccine Initiative. Also, this work was supported by an unrestricted grant from Sanofi Pasteur. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.